Novo Nordisk (NVO) shares have lost 5% in the past three months, which translates to approximately $29 billion in market value, against the industry’s growth of 2.6%. NVO has also underperformed in the sector and the S&P 500 in the past three months, as seen in the chart below.NVO Stock Underperforms the Industry, Sector & the S&P 500Image Source: Zacks Investment ResearchThe dip in the stock price was primarily observed after the company faced a major setback in July when the FDA rejected its regulatory fi ...